Elizabeth Cairns
Senior Writer
A journalist for more than two decades’ standing, Elizabeth has covered the pharma, biotech and medtech sectors in a variety of roles over the years. She moved to Scrip in 2023 from Vantage, where she specialised in cardiovascular therapies as well as obesity, diabetes and related metabolic disorders. Elizabeth has a degree in biochemistry from the University of Surrey.
Latest From Elizabeth Cairns
Altimmune Regains Some Momentum
Obesity drug pemvidutide looks better at nearly a year than it did at six months, but still lags rivals Wegovy and Zepbound.
Corporate VCs Play A Bigger Role In Hard Times
The investment wings of big biopharma are taking part in a larger proportion of VC deals than ever before.
BioCardia Aims To Defy Precedent With A Cardiac Cell Therapy
Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?
Dupixent Heralds The Age Of Biologics In COPD
A second pivotal hit positions Sanofi and Regeneron’s antibody for approval in COPD – but other biologics are coming fast.
The Future Of Obesity
Novo Nordisk and Eli Lilly are duking it out in the market, but dozens of competitors are waiting in the wings.
AstraZeneca Wins The AKT Race With Truqap
The UK big pharma gets a first-in-class approval in breast cancer, but a challenger is emerging.